Citadel Advisors’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-31,400
| Closed | -$5.4M | – | 15468 |
|
|
2021
Q3 | $5.4M | Buy |
31,400
+15,800
| +101% | +$2.07M | ﹤0.01% | 4155 |
|
|
2021
Q2 | $1.96M | Sell |
15,600
-1,200
| -7% | -$151K | ﹤0.01% | 6678 |
|
|
2021
Q1 | $2.28M | Buy |
16,800
+7,000
| +71% | +$904K | ﹤0.01% | 6083 |
|
|
2020
Q4 | $1.25M | Sell |
9,800
-1,000
| -9% | -$117K | ﹤0.01% | 6310 |
|
|
2020
Q3 | $1.22M | Sell |
10,800
-21,000
| -66% | -$2.09M | ﹤0.01% | 5678 |
|
|
2020
Q2 | $3.03M | Buy |
31,800
+700
| +2% | +$67.5K | ﹤0.01% | 3851 |
|
|
2020
Q1 | $2.79M | Buy |
31,100
+19,600
| +170% | +$1.52M | ﹤0.01% | 3571 |
|
|
2019
Q4 | $610K | Buy |
11,500
+4,500
| +64% | +$205K | ﹤0.01% | 6486 |
|
|
2019
Q3 | $277K | Sell |
7,000
-5,600
| -44% | -$243K | ﹤0.01% | 7674 |
|
|
2019
Q2 | $518K | Sell |
12,600
-6,900
| -35% | -$286K | ﹤0.01% | 6771 |
|
|
2019
Q1 | $908K | Buy |
19,500
+5,500
| +39% | +$241K | ﹤0.01% | 5759 |
|
|
2018
Q4 | $610K | Sell |
14,000
-28,000
| -67% | -$1.4M | ﹤0.01% | 6096 |
|
|
2018
Q3 | $2.4M | Sell |
42,000
-34,200
| -45% | -$1.68M | ﹤0.01% | 4097 |
|
|
2018
Q2 | $3.7M | Buy |
76,200
+67,900
| +818% | +$2.47M | ﹤0.01% | 3192 |
|
|
2018
Q1 | $325K | Buy |
+8,300
| New | +$353K | ﹤0.01% | 6620 |
|
|
2017
Q4 | – | Sell |
-13,800
| Closed | -$515K | – | 8623 |
|
|
2017
Q3 | $515K | Buy |
13,800
+3,100
| +29% | +$108K | ﹤0.01% | 5279 |
|
|
2017
Q2 | $325K | Buy |
10,700
+1,100
| +11% | +$31.9K | ﹤0.01% | 5774 |
|
|
2017
Q1 | $254K | Buy |
+9,600
| New | +$253K | ﹤0.01% | 6130 |
|
|
2016
Q4 | – | Sell |
-5,800
| Closed | -$210K | – | 8080 |
|
|
2016
Q3 | $210K | Buy |
+5,800
| New | +$192K | ﹤0.01% | 6236 |
|
|
2016
Q1 | – | Sell |
-7,000
| Closed | -$341K | – | 8413 |
|
|
2015
Q4 | $341K | Sell |
7,000
-8,000
| -53% | -$288K | ﹤0.01% | 5039 |
|
|
2015
Q3 | $374K | Buy |
15,000
+6,600
| +79% | +$198K | ﹤0.01% | 5236 |
|
|
2015
Q2 | $266K | Sell |
8,400
-11,800
| -58% | -$381K | ﹤0.01% | 5926 |
|
|
2015
Q1 | $769K | Buy |
20,200
+17,900
| +778% | +$712K | ﹤0.01% | 4296 |
|
|
2014
Q4 | $90K | Sell |
2,300
-600
| -21% | -$20.9K | ﹤0.01% | 6733 |
|
|
2014
Q3 | $88K | Buy |
2,900
+2,100
| +263% | +$59.2K | ﹤0.01% | 6523 |
|
|
2014
Q2 | $27K | Buy |
+800
| New | +$26.8K | ﹤0.01% | 7148 |
|
Citadel Advisors's XLRN Position: Q4 2021 in Review
Citadel Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 23,399 shares — an estimated $4.03M sold.
Citadel Advisors first reported a position in XLRN in Q2 2014 and held it in 29 quarters. The position peaked at $51.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Citadel Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Citadel Advisors sold 23,399 Acceleron Pharma shares in Q4 2021, an estimated $4.03M.
- Citadel Advisors first reported a position in Acceleron Pharma in Q2 2014 and held it in 29 quarters.
- Citadel Advisors's Acceleron Pharma position peaked at $51.8M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.